https://www.onclive.com/view/sac-tmt-improves-pfs-and-os-is-under-fda-priority-review-in-previously-treated-endometrial-cancer2026-10-26T18:15:00Z2026-10-26T18:15:00Z https://www.onclive.com/view/early-ctdna-clearance-is-linked-to-improved-survival-with-pembrolizumab-plus-crt-in-hpv-negative2026-10-26T17:40:00.877Z2026-10-26T17:40:00.877Z https://www.onclive.com/view/savolitinib-combo-extends-pfs-in-frontline-egfr-mutated-nsclc-and-met-overexpression2026-10-26T17:07:31.535Z2026-10-26T17:07:31.535Z https://www.onclive.com/view/fda-approves-talazoparib-plus-enzalutamide-for-metastatic-hrr-apmn-s-prostate-cancer2026-10-26T16:55:52.465Z2026-10-26T16:55:52.465Z https://www.onclive.com/view/whole-genome-oncodetect-mrd-test-is-now-available-for-solid-tumors2026-10-26T16:55:00Z2026-10-26T16:55:00Z https://www.onclive.com/view/ris-rez-improves-pfs-vs-gemcitabine-docetaxel-relapsed-refractory-osteosarcoma2026-10-26T16:37:22.057Z2026-10-26T16:37:22.057Z https://www.onclive.com/view/clinical-trial-to-evaluate-blood-test-for-early-detection-of-breast-cancer2026-10-26T16:00:00Z2026-10-26T16:00:00Z https://www.onclive.com/view/trastuzumab-pamirtecan-improves-pfs-in-hr-her2-low-metastatic-breast-cancer2026-10-26T15:20:31.149Z2026-10-26T15:20:31.149Z https://www.onclive.com/view/fda-grants-breakthrough-therapy-designation-to-enzomenib-in-r-r-kmt2a-rearranged-acute-leukemia2026-10-26T15:18:41.114Z2026-10-26T15:18:41.114Z https://www.onclive.com/view/dr-swiecicki-on-first-line-amivantamab-plus-pembrolizumab-and-carboplatin-in-hnscc2026-10-26T15:14:45.593Z2026-10-26T15:14:45.593Z https://www.onclive.com/view/dr-long-on-interpath-001-data-for-intismeran-autogene-plus-pembrolizumab-in-resected-melanoma2026-10-26T15:00:00Z2026-10-26T15:00:00Z https://www.onclive.com/view/five-under-5-top-oncology-videos-for-the-week-of-10-182026-10-26T14:15:49.930Z2026-10-26T14:15:49.930Z https://www.onclive.com/view/niraparib-dostarlimab-plus-crt-displays-efficacy-but-has-toxicity-concerns-in-locally-advanced-hnscc2026-10-26T14:10:18.102Z2026-10-26T14:10:18.102Z https://www.onclive.com/view/access-monitoring-and-open-questions-in-tgct-management2026-10-26T13:33:00.095Z2026-10-26T13:33:00.095Z https://www.onclive.com/view/pimicotinib-maneuver-data-and-treatment-around-joint-replacement2026-10-26T13:32:57.685Z2026-10-26T13:32:57.685Z https://www.onclive.com/view/molecular-testing-and-reporting-of-exon-20-insertions2026-10-26T12:05:00Z2026-10-26T12:05:00Z https://www.onclive.com/view/symptom-driven-treatment-decisions2026-10-26T12:00:00Z2026-10-26T12:00:00Z https://www.onclive.com/view/sustained-benefit-of-adjuvant-olaparib-in-women-with-germline-brca1--and-brca2-associated-high-risk-her2-negative-early-breast-cancer-updated-results-from-the-olympia-phase-iii-trial2026-10-20T15:46:56.909Z2026-10-26T12:00:00Z https://www.onclive.com/view/biology-and-subtypes-of-egfr-exon-20-insertions2026-10-26T12:00:00Z2026-10-26T12:00:00Z https://www.onclive.com/view/torvutatug-samrotecan-elicits-responses-across-fra-expression-levels-in-platinum-resistant2026-10-26T10:43:26.913Z2026-10-26T10:43:26.913Z https://www.onclive.com/view/esmo-on-location-day-12026-10-25T20:04:59.356Z2026-10-25T20:04:59.356Z https://www.onclive.com/view/ivonescimab-plus-chemotherapy-improves-os-vs-durvalumab-plus-chemotherapy-in-first-line-biliary2026-10-25T18:55:58.677Z2026-10-25T18:55:58.677Z https://www.onclive.com/view/dr-chase-on-the-potential-role-of-b7-h4-targeted-adcs-in-platinum-resistant-ovarian-cancer2026-10-25T18:25:00Z2026-10-25T18:25:00Z https://www.onclive.com/view/clarity-gastric01-shows-os-benefit-with-sonesitatug-vedotin-in-pretreated-cldn18-2-gastroesophageal-carcinoma2026-10-25T17:59:23.783Z2026-10-25T17:59:23.783Z https://www.onclive.com/view/divarasib-improves-pfs-and-os-vs-sotorasib-or-adagrasib-in-pretreated-kras-g12c-mutated-nsclc2026-10-25T17:54:12.308Z2026-10-25T17:54:12.308Z https://www.onclive.com/view/saffron-data-reveal-new-global-soc-in-egfr-nsclc-with-met-overexpression-and-or-amplification-after-osimertinib2026-10-25T16:44:09.999Z2026-10-25T16:44:09.999Z https://www.onclive.com/view/tovecimig-plus-paclitaxel-improves-orr-vs-paclitaxel-alone-in-biliary-tract-cancer2026-10-24T19:45:00Z2026-10-24T19:45:00Z https://www.onclive.com/view/lk101-plus-tislelizumab-elicits-responses-in-advanced-nsclc2026-10-24T18:13:16.216Z2026-10-24T18:13:16.216Z https://www.onclive.com/view/durvalumab-plus-enfortumab-vedotin-improves-survival-in-cisplatin-ineligible-mibc2026-10-24T18:08:37.823Z2026-10-24T18:08:37.823Z https://www.onclive.com/view/nrg-gy020-pembrolizumab-plus-radiation-fails-to-improve-rfs-in-dmmr-endometrial-cancer2026-10-24T17:54:05.664Z2026-10-24T17:54:05.664Z https://www.onclive.com/view/dellphi-305-data-support-frontline-maintenance-tarlatamab-plus-durvalumab-as-a-new-soc-in-es-sclc2026-10-24T17:45:41.621Z2026-10-24T17:45:41.621Z https://www.onclive.com/view/adjuvant-intismeran-autogene-plus-pembrolizumab-improves-rfs-and-dmfs-in-melanoma2026-10-24T17:20:48.059Z2026-10-24T17:20:48.059Z https://www.onclive.com/view/dasl-hicap-darolutamide-plus-adt-and-radiation-therapy-improves-mfs-in-very-high-risk-localized2026-10-24T17:18:17.639Z2026-10-24T17:18:17.639Z https://www.onclive.com/view/inca33890-plus-soc-elicits-responses-and-is-tolerable-across-in-first--and-third-line-mss-crc2026-10-24T17:00:00Z2026-10-24T17:00:00Z https://www.onclive.com/view/dr-feldman-on-ixotatug-vedotin-in-heavily-pretreated-recurrent-germ-cell-tumors2026-10-24T16:58:18.413Z2026-10-24T16:58:18.413Z https://www.onclive.com/view/first-line-dato-dxd-improves-intracranial-outcomes-in-immunotherapy-ineligible-tnbc-with-brain2026-10-24T16:56:38.963Z2026-10-24T16:56:38.963Z https://www.onclive.com/view/durvalumab-plus-bcg-improves-dfs-in-papillary-only-bcg-naive-high-risk-nmibc-in-potomac2026-10-24T16:53:46.503Z2026-10-24T16:53:46.503Z https://www.onclive.com/view/durvalumab-plus-olaparib-improves-os-in-advanced-endometrial-cancer2026-10-24T16:38:35.396Z2026-10-24T16:38:35.396Z https://www.onclive.com/view/perioperative-enfortumab-vedotin-plus-pembrolizumab-does-not-compromise-qol-in-cisplatin-eligible-mibc2026-10-24T16:05:05.423Z2026-10-24T16:05:05.423Z https://www.onclive.com/view/ctdna-analyses-from-crown-identify-predictors-of-early-progression-with-first-line-lorlatinib2026-10-24T15:24:23.245Z2026-10-24T15:24:23.245Z https://www.onclive.com/view/dr-enke-on-interim-safety-data-for-lutetium-lu-177-vipivotide-tetraxetan-retreatment-in-mcrpc2026-10-24T14:53:39.100Z2026-10-24T14:53:39.100Z https://www.onclive.com/view/t-dxd-followed-by-thp-elicits-deep-mri-responses-in-her2-early-breast-cancer2026-10-24T14:05:10.321Z2026-10-24T14:05:10.321Z https://www.onclive.com/view/final-os-postmonarch-favors-abemaciclib-plus-fulvestrant-hr-her2-advanced2026-10-24T13:58:02.712Z2026-10-24T13:58:02.712Z https://www.onclive.com/view/dr-westin-on-interim-overall-survival-data-from-duo-e-in-advanced-or-recurrent-endometrial-cancer2026-10-24T13:46:00Z2026-10-24T13:46:00Z https://www.onclive.com/view/incb123667-plus-bevacizumab-shows-antitumor-activity-in-recurrent-epithelial-ovarian-cancer2026-10-24T13:25:54.532Z2026-10-24T13:25:54.532Z https://www.onclive.com/view/atirmociclib-plus-fulvestrant-improves-pfs-hr-her2-advanced-breast-cancer2026-10-24T12:44:30.339Z2026-10-24T12:44:30.339Z https://www.onclive.com/view/panku-breast01-iza-bren-improves-pfs-vs-chemotherapy-pretreated-hr-her2-advanced-breast-cancer2026-10-24T12:18:59.027Z2026-10-24T12:18:59.027Z https://www.onclive.com/view/the-oncfive-top-oncology-articles-for-the-week-of-10-18-20262026-10-24T12:00:00Z2026-10-24T12:00:00Z https://www.onclive.com/view/ixotatug-vedotin-elicits-responses-in-heavily-pretreated-recurrent-germ-cell-tumors2026-10-24T11:55:59.175Z2026-10-24T11:55:59.175Z https://www.onclive.com/view/keynote-b15-ctdna-analysis-perioperative-ev-pembrolizumab-higher-ctdna-clearance-mibc2026-10-23T23:36:28.737Z2026-10-23T23:36:28.737Z https://www.onclive.com/view/pembrolizumab-plus-chemo-misses-efs-end-point-in-cisplatin-eligible-mibc2026-10-23T23:00:00Z2026-10-23T23:00:00Z https://www.onclive.com/view/sacituzumab-govitecan-triplet-elicits-durable-responses-in-treatment-naive-metastatic-urothelial-cancer2026-10-23T22:50:46.714Z2026-10-23T22:50:46.714Z https://www.onclive.com/view/surufatinib-plus-serplulimab-and-chemo-shows-activity-in-first-line-extrapulmonary-nec2026-10-23T20:41:23.424Z2026-10-23T20:41:23.424Z https://www.onclive.com/view/ad-hoc-analysis-supports-contributions-of-both-enfortumab-vedotin-and-pembrolizumab-in-cisplatin-ineligible-mibc2026-10-23T20:36:40.500Z2026-10-23T20:36:40.500Z https://www.onclive.com/view/adjuvant-giredestrant-preserves-qol-with-sustained-tolerability-in-er-her2-early-breast-cancer2026-10-23T18:40:00Z2026-10-23T18:40:00Z https://www.onclive.com/view/arcotatug-tavatecan-improves-survival-in-cldn18-2-advanced-gastric-or-gej-adenocarcinoma2026-10-23T17:19:43.517Z2026-10-23T17:19:43.517Z https://www.onclive.com/view/adding-uv1-vaccine-to-olaparib-durvalumab-maintenance-misses-pfs-end-point-in-brca-wild-type-recurrent-ovarian-cancer2026-10-23T17:11:11.668Z2026-10-23T17:11:11.668Z https://www.onclive.com/view/perioperative-nivolumab-plus-neoadjuvant-chemotherapy-misses-co-primary-end-points-in-mibc2026-10-23T16:10:50.484Z2026-10-23T16:10:50.484Z https://www.onclive.com/view/roswell-park-team-finds-potential-key-to-chemotherapy-resistance-in-triple-negative-breast-cancer2026-10-23T16:00:00Z2026-10-23T16:00:00Z https://www.onclive.com/view/daraxonrasib-improves-os-across-ras-genotype-and-treatment-subgroups-in-previously-treated2026-10-23T15:59:16.865Z2026-10-23T15:59:16.865Z https://www.onclive.com/view/teclistamab-monotherapy-wins-eu-approval-for-r-r-myeloma-after-at-least-1-prior-therapy2026-10-23T15:17:26.691Z2026-10-23T15:17:26.691Z https://www.onclive.com/view/ubamatamab-activity-in-recurrent-low-grade-serous-ovarian-cancer2026-10-23T12:00:00Z2026-10-23T12:00:00Z https://www.onclive.com/view/onclive-weekly-news-quiz-10-23-2026-did-you-miss-crucial-rectal-bladder-and-kidney-cancer-updates-2026-10-23T12:00:00Z2026-10-23T12:00:00Z https://www.onclive.com/view/polls-reveal-top-picks-for-lung-cancer-abstracts-of-interest-at-esmo-20262026-10-23T11:55:00Z2026-10-23T11:55:00Z https://www.onclive.com/view/poll-results-highlight-gynecologic-cancer-abstracts-of-interest-at-esmo-20262026-10-23T11:10:00Z2026-10-23T11:10:00Z https://www.onclive.com/view/dr-nghiemphu-on-how-the-nccn-inclusion-of-brigatinib-expands-access-for-nf2-related-schwannomatosis2026-10-23T00:00:00Z2026-10-23T00:00:00Z https://www.onclive.com/view/her2-mcrc-treatment-sequencing-favors-tucatinib-plus-trastuzumab-before-t-dxd2026-10-22T19:45:00Z2026-10-22T19:45:00Z https://www.onclive.com/view/fda-grants-full-approval-to-pembrolizumab-for-unresectable-metastatic-tmb-h-solid-tumors2026-10-22T19:15:03.587Z2026-10-22T19:15:03.587Z https://www.onclive.com/view/sbe303-receives-fda-fast-track-designation-in-pretreated-urothelial-cancer2026-10-22T17:56:52.631Z2026-10-22T17:56:52.631Z https://www.onclive.com/view/fda-grants-orphan-drug-designation-to-onvansertib-for-chronic-myelomonocytic-leukemia2026-10-22T17:05:57.456Z2026-10-22T17:05:57.456Z https://www.onclive.com/view/roginolisib-demonstrates-preliminary-activity-in-metastatic-uveal-melanoma2026-10-22T16:29:26.139Z2026-10-22T16:29:26.139Z https://www.onclive.com/view/ut-md-anderson-s-albert-koong-and-katy-rezvani-elected-to-the-national-academy-of-medicine2026-10-22T16:00:00Z2026-10-22T16:00:00Z https://www.onclive.com/view/dr-oberstein-on-the-rationale-for-evaluating-the-pd-1-il-15-fusion-protein-sar445877-in-mss-crc2026-10-21T21:15:00Z2026-10-21T21:15:00Z https://www.onclive.com/view/experts-tackle-key-questions-on-cdk4-6-inhibition-across-hr-breast-cancer-settings2026-10-21T20:38:41.376Z2026-10-21T20:38:41.376Z https://www.onclive.com/view/pembrolizumab-plus-enfortumab-vedotin-earns-ec-approval-in-resectable-mibc2026-10-21T19:57:43.588Z2026-10-21T19:57:43.588Z https://www.onclive.com/view/tolerability-remains-a-trop2-directed-adc-hurdle-in-egfr-mutated-nsclc2026-10-21T19:50:00Z2026-10-21T19:50:00Z https://www.onclive.com/view/dr-sinicrope-on-crc-abstracts-to-watch-at-the-2026-esmo-congress2026-10-21T16:30:00Z2026-10-21T16:30:00Z https://www.onclive.com/view/body-composition-changes-on-ct-scans-may-help-identify-pancreatic-cancer-risk2026-10-21T16:00:00Z2026-10-21T16:00:00Z https://www.onclive.com/view/beyond-pd-l1-refining-first-line-treatment-decisions-in-metastatic-nsclc2026-10-21T15:40:00Z2026-10-21T15:40:00Z https://www.onclive.com/view/lisaftoclax-plus-acalabrutinib-received-breakthrough-therapy-designation-in-china-for-treatment-naive-cll-sll2026-10-21T14:58:00.552Z2026-10-21T14:58:00.552Z https://www.onclive.com/view/order-both-ihc-and-ngs-defining-met-alterations-and-positioning-telisotuzumab-vedotin-in-non-small-cell-lung-cancer2026-10-21T14:45:50.037Z2026-10-21T14:45:50.037Z https://www.onclive.com/view/fda-approval-of-dostarlimab-brings-potential-organ-sparing-approach-in-dmmr-locally-advanced-rectal-cancer2026-10-21T13:00:00Z2026-10-21T13:00:00Z https://www.onclive.com/view/clinical-pearls-for-multiple-myeloma-management2026-10-21T12:05:00Z2026-10-21T12:05:00Z https://www.onclive.com/view/combination-strategies-and-sequencing-in-relapsed-refractory-multiple-myeloma2026-10-21T12:05:00Z2026-10-21T12:05:00Z https://www.onclive.com/view/next-generation-ctla-4-therapy-in-squamous-nsclc2026-10-21T12:05:00Z2026-10-21T12:05:00Z https://www.onclive.com/view/delivering-therapy-beyond-the-trial-setting2026-10-21T12:05:00Z2026-10-21T12:05:00Z https://www.onclive.com/view/emerging-post-immunotherapy-strategies-in-renal-cell-carcinoma2026-10-21T12:05:00Z2026-10-21T12:05:00Z https://www.onclive.com/view/monitoring-immune-toxicities-in-squamous-nsclc2026-10-21T12:00:00Z2026-10-21T12:00:00Z https://www.onclive.com/view/treatment-sequencing-in-multiple-myeloma2026-10-21T12:00:00Z2026-10-21T12:00:00Z https://www.onclive.com/view/administering-axatilimab-from-order-to-observation2026-10-21T12:00:00Z2026-10-21T12:00:00Z https://www.onclive.com/view/sequencing-targeted-therapy-in-advanced-renal-cell-carcinoma2026-10-21T12:00:00Z2026-10-21T12:00:00Z https://www.onclive.com/view/access-community-implementation-and-guideline-updates-in-relapsed-refractory-multiple-myeloma2026-10-21T12:00:00Z2026-10-21T12:00:00Z https://www.onclive.com/view/her2-maintenance-therapy-approvals-and-innovative-brain-metastasis-care-reshape-breast-cancer-management2026-10-20T21:35:00Z2026-10-20T21:35:00Z https://www.onclive.com/view/treatment-tailoring-and-weighing-alternative-formulations-support-optimal-tki-deployment-in-cml2026-10-20T20:40:45.232Z2026-10-20T20:40:45.232Z https://www.onclive.com/view/casdatifan-demonstrates-activity-in-advanced-clear-cell-rcc2026-10-20T19:27:15.320Z2026-10-20T19:27:15.320Z https://www.onclive.com/view/dr-margol-on-an-optimal-diagnostic-workflow-in-pediatric-low-grade-glioma2026-10-20T17:25:00Z2026-10-20T17:25:00Z https://www.onclive.com/view/qtx3034-plus-cetuximab-receives-fda-fast-track-designation-in-kras-g12d-mutated-crc2026-10-20T16:05:00Z2026-10-20T16:05:00Z https://www.onclive.com/view/mimivax-and-roswell-park-announce-results-from-phase-2b-survive-trial-of-survaxm-in-newly-diagnosed-glioblastoma2026-10-20T16:00:00Z2026-10-20T16:00:00Z https://www.onclive.com/view/pd-l1-level-histology-and-toxicity-profile-guide-frontline-ici-selection-in-nsclc2026-10-20T15:43:52.842Z2026-10-20T15:43:52.842Z https://www.onclive.com/view/fda-grants-fast-track-designation-to-mc001-in-pancreatic-cancer2026-10-20T15:11:47.391Z2026-10-20T15:11:47.391Z